Daiichi Sankyo announces TaNeDS Europe 2017 collaborative drug discovery programme

Daiichi SankyoDaiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced details of the application for its Take a New Challenge for Drug Discovery (TaNeDS) Europe 2017, a collaborative drug discovery initiative for universities and research institutes in Europe. TaNeDS programme was launched in Japan in 2011 to help discover new lines of research through open innovation. From 2013, it has expanded outside of Japan, opening up to researchers in Germany, Switzerland and Austria and became known as TaNeDS Global Programme. Since 2014, it has expanded further across Europe to include all EU member states and was renamed "TaNeDS Europe" in 2015. The aim of this programme is increasing collaborative opportunities with researchers in Europe.

About TaNeDS Europe 2017 Collaborative Drug Discovery Programme

1. Eligible Countries

All EU member states plus Iceland, Norway, Switzerland and Israel

2. Candidate Research for Application

New drug-target discovery, drug-target validation, and innovative technological research that could result in novel drug discovery and development

3. Research Themes

(1) Cancer

New mechanisms and drug-target validation study for small-molecule and biologic treatments (antibody drugs, etc.)

(2) Pain and Sensory Neuron Disorder

New mechanisms and drug treatments for pain and sensory neuronal systems in vision/hearing loss

(3) End-Organ Diseases

New targets and mechanisms of end-organ diseases from heart, kidney, liver and vascular diseases

(4) Other Internal Diseases

New mechanisms and drug treatments for rare diseases, gastrointestinal disorder and anaemia

(5) Cell Therapy

Research on novel somatic stem/progenitor cells, adoptive T-cell therapy and new technology on cell/gene modification

(6) Revolutionary Drug Discovery Technology

Novel technology on oncology, nucleic acid therapeutics, gene therapy and drug metabolism and pharmacokinetics

For more details, please visit TaNeDS Europe webpage at: http://www.daiichisankyo.com/rd/taneds/index.html

4. Budget and Period of Research

Depending on the project type, up to maximum of 80,000 (Type A) or 150,000 (Type B) euros (plus overhead) per year for collaborative research projects for 2 years

5. Eligibility

Researchers of any nationality employed by universities, research institutes and start-up companies within the EU as well as Iceland, Norway, Switzerland and Israel, who can conduct research in those countries

6. Selection criteria

By matching Daiichi Sankyo's research interests as well as demonstrating originality, potentiality and possibility of drug discovery

7. Schedule

Application period: January 10 to February 20, 2017

First shortlist selection period: Late February to Mid-March, 2017

Second shortlist selection period: April, 2017

On-site visit interview: Mid-May, 2017

Notification of final decisions: Early June, 2017

Start of research programmes: August 2017 and onward

About Selection Results for TaNeDS Europe 2015/2016 Collaborative Drug Discovery Programme

The selection for 2015/2016 resulted in four projects, and the three collaborations are currently underway having one under negotiation.

(1) Applications: 191

(2) Selected: 4

The themes of four selected proposals are Cancer Biologics (Switzerland), Sensory Neuron (the Netherlands), Rare Diseases (Ireland), and Anaemia (Sweden).

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...

Tezepelumab granted Breakthrough Therapy Designati…

AstraZeneca and its partner Amgen Inc. (Amgen) today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tezepelumab...